BioCryst Pharmaceuticals, Inc.
BCRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, BioCryst Pharmaceuticals, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. With a market capitalization of $1.95B, it sits in small-cap territory. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Market Cap
$1.95B
Beta
0.55
P/E (TTM)
—
P/E (Fwd)
7.65
EPS (TTM)
$-1.40
EPS (Fwd)
$1.00
ROE
—
ROA
52.9%
Cash
$352.6M
Total Debt
$836.6M
Free CF
$323.7M
52W Change
4.7%
Annual Financials
Cash vs Debt
Where BCRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BCRX finished 11.90% below its 150-day moving average ($9.16) and 7.35% below its 200-day moving average ($8.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BCRX overbought or oversold?
At the October 20, 2026 close, BCRX's RSI(14) was 45.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BCRX has $352.6M in cash with $836.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $323.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on assets of 52.9% further supports the picture of efficient asset utilization. Revenue has grown from $270.8M (2022) to $874.8M (2025), reflecting a 223% increase over the period.
With a beta below 0.7, BioCryst Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BioCryst Pharmaceuticals, Inc.'s trajectory.